Roman Butler Fullerton & Co. Sells 1,663 Shares of CVS Health Co. (NYSE:CVS)

Roman Butler Fullerton & Co. cut its stake in shares of CVS Health Co. (NYSE:CVS) by 12.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,813 shares of the pharmacy operator’s stock after selling 1,663 shares during the period. Roman Butler Fullerton & Co.’s holdings in CVS Health were worth $862,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in shares of CVS Health by 2.7% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 43,503 shares of the pharmacy operator’s stock valued at $3,434,000 after buying an additional 1,150 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in CVS Health by 6.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 115,101 shares of the pharmacy operator’s stock valued at $9,088,000 after acquiring an additional 6,899 shares during the last quarter. Oakworth Capital Inc. grew its position in shares of CVS Health by 38.5% in the 4th quarter. Oakworth Capital Inc. now owns 5,542 shares of the pharmacy operator’s stock valued at $438,000 after acquiring an additional 1,540 shares during the period. Archer Investment Corp increased its stake in shares of CVS Health by 7.2% during the 4th quarter. Archer Investment Corp now owns 40,808 shares of the pharmacy operator’s stock worth $3,222,000 after purchasing an additional 2,730 shares during the last quarter. Finally, Tyche Wealth Partners LLC bought a new stake in shares of CVS Health in the 4th quarter valued at about $202,000. 80.66% of the stock is currently owned by institutional investors.

CVS Health Price Performance

NYSE:CVS traded up $0.36 during trading hours on Thursday, reaching $68.96. 1,413,935 shares of the company were exchanged, compared to its average volume of 10,776,160. The company has a market capitalization of $86.92 billion, a P/E ratio of 10.71, a P/E/G ratio of 0.91 and a beta of 0.52. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. The business has a 50 day moving average of $75.53 and a 200 day moving average of $73.73. CVS Health Co. has a 1-year low of $64.41 and a 1-year high of $83.25.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. The company had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. During the same quarter last year, the business earned $1.99 earnings per share. CVS Health’s revenue was up 11.9% on a year-over-year basis. Research analysts forecast that CVS Health Co. will post 8.32 EPS for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.86%. The ex-dividend date is Friday, April 19th. CVS Health’s dividend payout ratio (DPR) is presently 41.18%.

Insider Buying and Selling

In other CVS Health news, EVP Prem S. Shah sold 29,473 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now directly owns 39,765 shares in the company, valued at $3,059,916.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.24% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wells Fargo & Company lowered their price target on CVS Health from $83.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Monday, April 8th. HSBC started coverage on CVS Health in a report on Friday, December 22nd. They set a “buy” rating and a $94.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $87.00 price objective on shares of CVS Health in a report on Wednesday, April 10th. Royal Bank of Canada cut their target price on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research note on Thursday, February 8th. Finally, Piper Sandler upped their price target on shares of CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus target price of $89.44.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.